Health
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today extended results of its ongoing Phase 2a trial of SGX302 (synthetic hypericin) for the treatment of mild-to-moderate psoriasis. In this extension (Cohort 3) of the exploratory phase of the study, an additional four patients were enrolled and treated with an improved topical
About this update from Soligenix, Inc.
[{"type":"text","content":"Optimized Gel Formulation Demonstrates Clinical Success in Third Cohort of Patients ","length":83,"tagName":"p","attribs":{}},{"type":"text","content":"PRINCETON, N.J., Dec. 17, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today extended results of its ongoing Phase 2a trial of SGX302 (synthetic hypericin) for the treatment of mild-to-moderate psoriasis. In this extension (Cohort 3) of the exploratory phase of the study, an additional four patients were enrolled and treated with an improved topical gel formulation of synthetic hypericin.","length":597,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Soligenix, Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Soligenix, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":112,"url":"https://media.zenfs.com/en/prnewswire.com/85ba4191e64f574a13cd0c133f4a3048"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/0bSTAeYRTNnLNEjUJiiRHg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE5NztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/85ba4191e64f574a13cd0c133f4a3048","width":400,"height":112}},"href":"https://mma.prnewswire.com/media/1768046/Soligenix_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The Cohort 3 patients were treated for the same 18-week period as Cohorts 1 and 2, but utilized an optimized gel formulation of synthetic hypericin. The gel formulation was specifically designed to improve ease of application to larger areas of the skin. SGX302 gel therapy was well tolerated by all patients with no drug related adverse events identified. On average over the three evaluable patients (one patient discontinued for personal reasons), there were improvements in the Investigator Global Assessment (IGA), the Psoriasis Activity and Severity Index (PASI), the simplified psoriasis index, the dermatology life quality index and the Skindex-29 questionnaire. One patient achieved a disease status of "Almost Clear" using the IGA, which is considered a standard clinical measure for treatment success in psoriasis, with a substantial improvement in their PASI score, exceeding 50%. These outcomes were very s...